Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 752

1.

Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.

Ernst ME, Fravel MA.

Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033. Review.

PMID:
20109996
2.

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.

N Engl J Med. 2005 Dec 8;353(23):2450-61.

3.

Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.

Yu KH.

Recent Pat Inflamm Allergy Drug Discov. 2007 Feb;1(1):69-75. Review.

PMID:
19075968
4.

Urate-lowering therapy for gout: focus on febuxostat.

Love BL, Barrons R, Veverka A, Snider KM.

Pharmacotherapy. 2010 Jun;30(6):594-608. doi: 10.1592/phco.30.6.594. Review.

PMID:
20500048
5.

Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.

Bruce SP.

Ann Pharmacother. 2006 Dec;40(12):2187-94. Epub 2006 Nov 28. Review.

PMID:
17132810
6.

An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.

Huang X, Du H, Gu J, Zhao D, Jiang L, Li X, Zuo X, Liu Y, Li Z, Li X, Zhu P, Li J, Zhang Z, Huang A, Zhang Y, Bao C.

Int J Rheum Dis. 2014 Jul;17(6):679-86. doi: 10.1111/1756-185X.12266. Epub 2014 Jan 28.

PMID:
24467549
7.

An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S13-8. doi: 10.1097/RHU.0b013e31821d36cc.

PMID:
21654265
8.

An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S44-9. doi: 10.1097/RHU.0b013e31821d352f. Erratum in: J Clin Rheumatol. 2014 Sep;20(6):E3. Naoyuki, Kamatani [Kamatani, Naoyuki]; Shin, Fujimori [corrected to Fujimori, Shin]; Toshikazu, Hada [corrected to Hada, Toshikazu]; Tatsuo, Hosoya [corrected to Hosoya, Tatsuo]; Kenjiro, Kohri [corrected to Kohri, Kenjiro]; Toshitaka, Nakamura [corrected.

PMID:
21654269
9.

Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S35-43. doi: 10.1097/RHU.0b013e31821d351d. Erratum in: J Clin Rheumatol. 2014 Sep;20(6):E2. Naoyuki, Kamatani [corrected to Kamatani, Naoyuki]; Shin, Fujimori [corrected to Fujimori, Shin]; Toshikazu, Hada [corrected to Hada, Toshikazu]; Tatsuo, Hosoya [corrected to Hosoya, Tatsuo]; Kenjiro, Kohri [corrected to Kohri, Kenjiro]; Toshitaka, Nakamur.

PMID:
21654268
10.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.

Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

11.

Febuxostat for prevention of gout attacks.

Pohar S, Murphy G.

Issues Emerg Health Technol. 2006 Aug;(87):1-4.

PMID:
16958189
12.

Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S50-6. doi: 10.1097/RHU.0b013e31822541d0.

PMID:
21654270
13.
14.

Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S19-26. doi: 10.1097/RHU.0b013e31821d36de. Erratum in: J Clin Rheumatol. 2014 Sep;20(6):E1. Naoyuki, Kamatani [corrected to Kamatani, Naoyuki]; Shin, Fujimori [corrected to Fujimori, Shin]; Toshikazu, Hada [corrected to Hada, Toshikazu]; Tatsuo, Hosoya [corrected to Hosoya, Tatsuo]; Kenjiro, Kohri [corrected to Kohri, Kenjiro]; Toshitaka, Nakamur.

PMID:
21654266
15.

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

Jackson RL, Hunt B, MacDonald PA.

BMC Geriatr. 2012 Mar 21;12:11. doi: 10.1186/1471-2318-12-11.

16.

Febuxostat--treatment for hyperuricemia and gout?

Moreland LW.

N Engl J Med. 2005 Dec 8;353(23):2505-7. No abstract available.

PMID:
16339099
17.

Febuxostat: a new treatment for hyperuricaemia in gout.

Edwards NL.

Rheumatology (Oxford). 2009 May;48 Suppl 2:ii15-ii19. doi: 10.1093/rheumatology/kep088. Review.

PMID:
19447778
18.

Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.

Ye P, Yang S, Zhang W, Lv Q, Cheng Q, Mei M, Luo T, Liu L, Chen S, Li Q.

Clin Ther. 2013 Feb;35(2):180-9. doi: 10.1016/j.clinthera.2012.12.011. Epub 2013 Jan 16. Review.

PMID:
23332451
19.

Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.

Komoriya K, Hoshide S, Takeda K, Kobayashi H, Kubo J, Tsuchimoto M, Nakachi T, Yamanaka H, Kamatani N.

Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1119-22.

PMID:
15571213
20.

Febuxostat for the treatment of gout.

Bridgeman MB, Chavez B.

Expert Opin Pharmacother. 2015 Feb;16(3):395-8. doi: 10.1517/14656566.2015.985588. Epub 2015 Jan 5. Review.

PMID:
25556668

Supplemental Content

Support Center